-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TextSunshine
On April 11, Veru announced that sabizabulin (bisindole) reduced the relative risk of death by 55% in moderate-to-severe COVID-19 hospitalized patients
Affected by this news, Veru's shares rose 182%
Sabizabulin is an oral tubulin inhibitor developed by Veru, which blocks the intracellular transport of the new coronavirus along microtubules by inhibiting tubulin
This is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of sabizabulin in patients with moderate-to-severe COVID-19 at risk of acute respiratory distress syndrome (ARDS) and death
This release is an interim analysis of the first 150 patients enrolled